Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery
Launched by RENJI HOSPITAL · Mar 23, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≧ 65 years;
- • 2. ASA Ⅰ-Ⅲ;
- • 3. Elective major non-cardiac surgery;
- • 4. Voluntary signed informed consent.
- Exclusion Criteria:
- • 1. People with mental illness;
- • 2. Suffering from serious central nervous system disorders such as arkinson's disease, Alzheimer's disease, etc;
- • 3. Elevated intracranial pressure;
- • 4. Emergency or trauma surgery;
- • 5. Prior history of postoperative delirium or postoperative cognitive decline;
- • 6. The patient has impaired hearing or impaired vision;
- • 7. Suffering from severe systemic underlying diseases (e.g. cardiac insufficiency, malignant arrhythmia, malignant hypertension, hepatic failure, renal failure, etc.);
- • 8. The patient is in chronic pain;
- • 9. The patient is severely malnourished;
- • 10. Patients with stage 3 or 4 malignant tumors, pancreatic cancer, allbladder cancer, cholangiocarcinoma and other tumors with high malignancy and poor prognosis.
- • 11. history of allergy to or contraindication to esketamine;
- • 12. inability or unwillingness to complete questionnaires or clinical testing;
- • 13. Unable or unwilling to use a postoperative intravenous analgesic pump.
About Renji Hospital
Renji Hospital, a prestigious medical institution affiliated with Shanghai Jiao Tong University School of Medicine, is dedicated to advancing healthcare through innovative clinical research. With a strong emphasis on patient-centered care, Renji Hospital conducts a wide range of clinical trials across various therapeutic areas, harnessing cutting-edge technology and evidence-based practices. The hospital's multidisciplinary team of experienced researchers and medical professionals collaborates closely to ensure rigorous study design and execution, aiming to contribute significantly to medical knowledge and improve treatment outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported